Ep78: Does Rescheduling Marajuana Make Medical Cannabis More Attractive For Research?

In this insightful episode, we sit down with Pierre Van Weperen, CEO of Grow Pharma, to discuss the recent rescheduling of marijuana in the United States and its potential effects on the medical cannabis market. Join us as Pierre unpacks the regulatory changes, market dynamics, and future opportunities in the evolving landscape of medical cannabis.Show Highlights:1 . Introduction to ReschedulingOverview of the recent changes in marijuana scheduling in the US.Explanation of the difference between Schedule I and Schedule III substances.2 . Regulatory ImplicationsHow the rescheduling of marijuana impacts federal and state regulations.Changes in research restrictions and what this means for scientific studies.3 . Market DynamicsPotential shifts in the medical cannabis market due to rescheduling.Impact on pharmaceutical companies and cannabis producers.Changes in consumer access and insurance coverage for medical cannabis.4 . Future OpportunitiesEmerging trends in the medical cannabis industry.Opportunities for new product development and market expansion.The potential for international collaborations and market entry.5 . Challenges and ConsiderationsLegal and logistical challenges in implementing the rescheduling changes.Ethical considerations and the importance of patient safety.Addressing public and medical community perceptions about medical cannabis.6 . Q&A with Pierre Van WeperenTackling comments from the rescheduling document about the rescheduling and its potential impacts.Useful LinksYoutube ChannelElevate Health Chiropractic and Wellbeing WebsiteElevate Health Online Membership Registration